Skip to main navigation
Skip to search
Skip to main content
WashU Research Profiles Home
Help & FAQ
Link opens in a new tab
Search content at WashU Research Profiles
Home
Profiles
Research units
Research output
Inflammatory demyelinating neuropathies
Glenn Lopate
,
Alan Pestronk
Institute of Clinical and Translational Sciences (ICTS)
Section of Neuromuscular Medicine
Hope Center for Neurological Disorders
Research output
:
Contribution to journal
›
Review article
›
peer-review
9
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Inflammatory demyelinating neuropathies'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Human Immune System
100%
Demyelinating Neuropathy
100%
Immune Globulin
100%
Corticosteroids
71%
Plasma Exchange
71%
Guillain-Barré Syndrome
28%
Therapy Goals
28%
Therapy Choice
28%
Venous Access
28%
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
28%
Adverse Effects
14%
High Dose
14%
Initial Treatment
14%
Disease Severity
14%
Safety Profile
14%
Illness
14%
Moderate to Severe
14%
Cardiac Disease
14%
Age-related Risk
14%
Patient Response
14%
Hepatic Disease
14%
Intensive Care Unit
14%
Activities of Daily Living
14%
Every Other Day
14%
Drug Choice
14%
Severe Symptoms
14%
Multicenter Randomized Controlled Trial
14%
Supportive Care
14%
Functional Capacity
14%
Methylprednisolone
14%
Hemodynamic Instability
14%
Gait Disorders
14%
Enhanced Strength
14%
Treatment Costs
14%
Potential Drug Interactions
14%
Side Effect Profile
14%
Immunomodulatory Therapy
14%
Chronic Treatment
14%
Good Safety
14%
Sensory Loss
14%
Therapy Experiences
14%
Respiratory muscle Strength
14%
Controlled Comparison
14%
Autonomic Instability
14%
Second-line Agents
14%
Anti-GM1
14%
Anti-glycolipid Antibody
14%
Immune Plasma
14%
GQ1b
14%
Strength Abilities
14%
Well Tolerated
14%
Immunomodulatory Drugs (IMiDs)
14%
Symptom Treatment
14%
Mild Symptoms
14%
Bulbar Weakness
14%
Medicine and Dentistry
Human Immunoglobulin
100%
Demyelinating Neuropathy
100%
Plasma Exchange
71%
Corticosteroid
71%
Health Care Cost
28%
Contraindication
28%
Polyradiculoneuropathy
28%
Adverse Event
14%
Liver Disease
14%
Disease Severity
14%
Randomized Controlled Trial
14%
Hemodynamic
14%
Heart Disease
14%
Drug Megadose
14%
Intensive Care Unit
14%
Weakness
14%
Supportive Care
14%
Mouth
14%
Deterioration
14%
Drug Interaction
14%
Methylprednisolone
14%
Immunomodulating Agent
14%
Antiserum
14%
Gait Disorder
14%
Comparison Trial
14%
Diseases
14%
Side Effect
14%
Pharmacology, Toxicology and Pharmaceutical Science
Human Immunoglobulin
100%
Demyelinating Neuropathy
100%
Corticosteroid
71%
Syndrome
28%
Polyradiculoneuropathy
28%
Adverse Event
14%
Liver Disease
14%
Randomized Controlled Trial
14%
Disease Severity
14%
Heart Disease
14%
Immunomodulating Agent
14%
Drug Interaction
14%
Antiserum
14%
Deterioration
14%
Weakness
14%
Methylprednisolone
14%
Gait Disorder
14%
Comparison Trial
14%
Diseases
14%
Side Effect
14%